Premium Reports
Contact KLAS
 Download Report    Zoom in charts

Preferences

   Bookmark

Related Series

 No Related Series

 End chart zoom
Roche navify Tumor Board 2023 Roche navify Tumor Board 2023
* A page refresh may be necessary to see the updated image

Roche navify Tumor Board 2023
Improving Tumor Board Meetings with a Holistic View of Data That Facilitates Multidisciplinary Team Collaboration and Optimizes Care Decisions

author - Everton Santos
Author
Everton Santos
author - Spencer Corbett
Author
Spencer Corbett
 
October 25, 2023 | Read Time: 1  minute

Tumor board conferences play a crucial role in the comprehensive, effective management of cancer patients. These meetings involve a multidisciplinary team that collectively evaluates complex cancer cases and collaborates to make informed, personalized treatment decisions. The absence of tumor board technology can hinder effective communication, collaboration, data sharing, and decision-making, which potentially leads to delays, inaccuracies, and suboptimal care. Roche aims to solve these potential problems with navify Tumor Board. This report offers an initial look at customers’ experiences with this product.

to see the full dataset.

If you don't have a login, getting started is easy.

Provider Organizations
Fill out our registration form to verify your organization.
HIT Companies
Contact a KLAS representative for plans and pricing.

Key Findings:

  1. navify Tumor Board Customer Experience: An Initial Look
  2. Points to Ponder
  3. Roche Diagnostics: Company Profile at a Glance
  4. Solution Technical Specifications (provided by Roche Diagnostics)
author - Kyle Chilton
Project Manager
Kyle Chilton
 Download Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.